



Press release June 29, 2012

## **Genovis Signs Exclusive Distribution Agreement with Sigma-Aldrich® for Sales in Asia, Southeast Asia and South America**

Genovis announced today that it has signed an exclusive distribution agreement with Sigma-Aldrich Corporation (NASDAQ: SIAL) that enables the sale of Genovis products in about 50 countries across Asia, Southeast Asia and South America. The agreement grants exclusive rights in the countries concerned, and includes existing products in the Genovis protein engineering portfolio.

“I am extremely pleased that we have signed an agreement with one of the world’s strongest players in supplying the life science community with biochemical and organic chemical products, kits and services. Our goal is to reach out to the rapidly growing Asian and South American markets and this is an excellent solution for us. I am proud that Sigma-Aldrich has elected to include our products as part of its comprehensive line of products, reagents and kits, and I look forward to cooperating with the company’s fantastic team, which truly understands our customers. Together, we have the ability to reach and serve the many new customers in these markets,” stated Sarah Fredriksson, CEO of Genovis.

Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.

For more information, please contact:

Sarah Fredriksson, CEO, Genovis AB

T: +46 (0)46-10 12 35

E: sarah.fredriksson@genovis.com

### **About Genovis**

Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The products launched to date are aimed at customers who work with development of drugs, new diagnostic methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on design, production and characterization of nanostructures as contrast agents in medical imaging. The nanostructures and methods that Genovis focuses on can also be used as carriers of various substances in the development of new drug delivery methods. The projects are mainly in-house, but also include collaborations with research groups, including at Lund University.

*Sigma-Aldrich is a registered trademark of Sigma-Aldrich Co. LLC and used with permission.*

*Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00*